Suche Bilder Maps Play YouTube News Gmail Drive Mehr »
Erweiterte Patentsuche | Webprotokoll | Anmelden

Patente

VeröffentlichungsnummerUS5690681 A
PublikationstypErteilung
Anmeldenummer08/624,109
Veröffentlichungsdatum25. Nov. 1997
Eingetragen29. März 1996
Prioritätsdatum
29. März 1996
Auch veröffentlicht unter
Erfinder
Ursprünglich Bevollmächtigter
US-Klassifikation
Internationale Klassifikation
Unternehmensklassifikation
Europäische Klassifikation
A61N 1/36Z3J
Referenzen
Externe Links
Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US 5690681 A
Zusammenfassung

A closed-loop variable frequency vagal stimulation apparatus for control of ventricular rate during atrial fibrillation. In one embodiment the apparatus includes a stimulator applied to the left vagus nerve and a proportional controller programmed to automatically and continuously adjust the vagal stimulation frequency proportionally as a function of the difference between actual and desired ventricular excitation rates. In a second embodiment the apparatus includes a vagal nerve stimulator and a controller which automatically adjusts the vagal stimulation frequency as a function of the difference between ventricular excitation rate and arterial pulse rate in order to eliminate or minimize pulse deficit.

Ansprüche
We claim:

1. An apparatus for automatically controlling ventricular rate by vagal stimulation to minimize pulse deficit during atrial fibrillation, comprising:

stimulating means for stimulating a vagal nerve at a variable stimulation frequency;

means for detecting a ventricular excitation rate;

means for detecting an arterial pulse rate;

processing means for comparing said ventricular excitation rate and said arterial pulse rate and automatically adjusting said vagal stimulation frequency as a function of the difference between said ventricular excitation rate and said arterial pulse rate.

2. The apparatus of claim 1, wherein said processing means includes means for adjusting the vagal stimulation frequency as a function of the ratio of said ventricular excitation rate to said arterial pulse rate.

3. The apparatus of claim 2, wherein said processing means increases said vagal stimulation frequency at predetermined intervals until said pulse deficit is substantially eliminated.

4. The apparatus of claim 3, further comprising means for enabling generation of stimulating pulses only in the presence of atrial fibrillation.

5. The apparatus of claim 3, in which the predetermined interval is in the range of approximately one to ten minutes.

Beschreibung
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

For the purposes of promoting an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated device, and such further applications of the principles of the invention as illustrated therein being contemplated as would normally occur to one skilled in the art to which the invention relates.

FIG. 1 illustrates an implantable device according to the present invention in its operating environment in a mammalian body, in which it is operatively connected to the heart and the left vagus nerve. Information on the electrical activity of the ventricles and the atria is obtained by a catheter having two pairs of electrodes: electrodes 1 and 2 in the right ventricle (RV) and electrodes 3 and 4 in the right atrium (RA). Electrodes 1 and 2 are designed and positioned to detect a ventricular electrogram, which is supplied to the implanted controller unit 10 which processes the ventricular electrogram and derives therefrom the ventricular excitation rate. Electrodes 3 and 4 are designed and positioned to detect an atrial electrogram, which is supplied via the catheter to the implanted control unit, which processes the atrial electrogram. The implanted control unit includes logic circuitry or other circuit means for comparing the atrial and ventricular signals in terms of synchronization and rate, and on the basis of that comparison determining whether or not the patient is experiencing atrial fibrillation. The implantable device includes a pair of electrodes 5 and 6 attached or adjacent to the left vagus nerve for controlled stimulation thereof. One embodiment of the present invention, described below, also includes a sensor of instantaneous blood pressure, in the form of a monopolar impedance-measuring electrode applied to the surface of the subclavian (SC) artery. Alternately, a piezoelectric pulse pickup placed alongside an artery could be used. A piezoelectric device would generate a voltage pulse and therefore save battery life in an implanted control unit dependent on a battery for operation.

The two embodiments of the invention to be described below are desirably combined in a single implanted control unit operable in two modes respectively associated with the control algorithms for the first and second embodiments. Both embodiments use an adaptive control system which adjusts to changing cardiac states. It operates only during episodes of atrial fibrillation. It retains, in memory, parameters that were successful in previous episodes of required control and uses this previously learned information to improve controller responses under similar situations. It also uses this information to accelerate controller adjustments in newly encountered situations.

The first embodiment and its associated algorithm will be described in connection with FIG. 2, which depicts in block diagram form, a controller 20 as an important aspect of the implanted control unit. The ventricular and atrial signals are supplied from their respective electrodes in the heart to a ventricular electrogram detector 22 and atrial electrogram detector 24, respectively, which digitize the electrograms and supply the digitized signals to controller 20, which responds to the detected ventricular and atrial signals. More specifically, atrial rate is determined on the basis of the interval between atrial waves and is compared to a threshold established as an indication of atrial fibrillation. If desired, the time interval itself may be measured and compared to a time interval threshold for the same purpose. Other techniques and algorithms for detection of atrial fibrillation with a lead configuration of multiple catheters including one in the right atrium and another in the coronary sinus are disclosed in an article by Kim et al. entitled "An Atrial Fibrillation Detection Algorithm for an Implantable Atrial Defibrillator", Computers in Cardiology, 1995, IEEE 1995: 169-172, which article is hereby incorporated by reference.

In the presence of atrial fibrillation, the controller is enabled to compare the actual R-wave rate with a target rate 25 entered into the controller via an external programmer 26 (FIG. 1) and, based on the difference between those rates, to control the frequency of the pulses which are generated by a stimulator 28 connected via electrodes 5 and 6 to the left vagus nerve. The controller is preferably programmed to apply a low initial frequency, and consequently, to increase the stimulus frequency slowly and incrementally until the ventricular rate matches the operator-selected target rate, and to automatically and continuously adjust the vagal stimulation frequency as a function of the difference between the actual and desired ventricular excitation rates. FIG. 4 illustrates the smooth control of ventricular rate that can be exerted by vagal stimulation during atrial fibrillation. A steady increase in stimulation frequency enabled the ventricular rate to be decreased smoothly, in an almost linear manner, down to a rate of 35 bpm with a stimulation frequency of 10 pulses/second. A pulse width of 100 microseconds (μsec.) has been found suitable, and pulse widths up to 2 msec. may also be effective in some applications. The pulse width is preferably in the range of 100-200 μsec. for A and B fibers, and in the range of 500-750 μsec. for C fibers. A suitable implantable stimulator is described in detail in U.S. Pat. No. 5,154,172, which is hereby incorporated by reference.

Referring to FIG. 3, the second embodiment or mode of the present invention operates according to an algorithm designed for elimination of a pulse deficit, i.e., the condition in which an arterial pulse fails to occur in response to an R wave. This algorithm does not require the selection of a target ventricular rate and is therefore operator-independent. The objective of this closed-loop control method is to identify the lowest stimulus frequency required be applied to the left vagus nerve to achieve a ventricular rate with no pulse deficit. As will be described, the controller 30 is designed and programmed to monitor the blood pressure signal for an arterial pulse after every ventricular excitation (as indicated by the R wave of the ECG), and, in general terms, to use the pulse deficit to control the frequency of stimuli applied to the left vagus nerve in order to identify the minimum stimulus frequency for which each ventricular excitation produces a blood pressure pulse. The controller is programmed to implement an algorithm corresponding generally to the graph illustrated in FIG. 5, although it will be understood that the shape and values of such a graph will vary somewhat for individual patients and that the automatic control algorithm will be varied accordingly. The ventricular and atrial electrogram detectors 22 and 24 digitize the electrogram signals and supply them to the controller, which also receives digitized data from an arterial pulse detector 32, described in further detail below.

There are several important considerations in achieving closed-loop control to eliminate the pulse deficit in atrial fibrillation. The first is recognition that inhibition of impulses traveling from the atria to the ventricles using vagus stimulation is not instantaneous. From the initiation of a train of stimuli applied to the vagus nerve, the onset of slowing of the ventricular (R wave) rate depends somewhat on the frequency of the stimuli in the train; the higher the frequency, the sooner the onset of ventricular slowing.

Another important consideration is adoption of an amplitude criterion for pulse counting. During atrial fibrillation, the arterial pulses vary widely in amplitude. However, a pulse should occur in a time window just after the R wave of the ECG, and so the R wave is preferably used to open a time window to measure the peak-to-peak amplitude of the arterial pulse in the window, which is sufficiently long to accommodate the isovolumic period and the pulse transit time to the arterial measuring site. In a typical situation the former is on the order of 150 msec. and with a measuring site close to the left ventricle, the latter may amount to 50-100 msec. A running average of the pulse amplitude is made, and each newly measured pulse is compared in amplitude to the mean pulse amplitude. Pulses less than a predetermined percentage (20% is presently preferred) of the mean pulse amplitude are treated as absent.

The amount of pulse deficit, is identified by the relationship between R waves and arterial pulse waves over a predetermined interval of time, for example, one minute. The controller's response to a pulse deficit is to apply low-frequency stimuli, e.g., initially 1 pulse per second, via stimulator 28. Controller 30 then counts and displays the ratio of R waves to arterial pulses. After 1 minute, if the pulse deficit has not been reduced, the controller increases the frequency of the stimuli applied to the vagus nerve to 2 pulses per second and evaluates the pulse deficit over the next one-minute period. This procedure of evaluating pulse deficit and incrementally increasing stimulus frequency continues until the pulse deficit disappears, or until a low R-wave rate safety limit is reached, at which point the controller maintains the current stimulus frequency.

An arterial pulse detector 32 for measuring arterial pulse rate and suitable for use with the present invention includes a monopolar arterial electrode made from a Teflon-coated stainless steel wire, insulated except at its distal end, which is sutured to a small sheet of Dacron-reinforced Silastic. The Dacron sheet carrying the electrode is wrapped around the subclavian artery as shown in FIG. 1, or other convenient artery, and sutured. The monopolar arterial electrode operates in conjunction with a reference electrode which is relatively large and located at any convenient site, for example, the metal case of the implanted control unit. Further details of an arterial pulse detector as described above are described in an article by Konrad et al. entitled "A New Implantable Arterial Pulse Sensor for Detection of Ventricular Fibrillation," Medical Instrumentation 22(6):304-311, December, 1988, which article is hereby incorporated by reference. Alternatively, and especially for experimental studies, the arterial pulse may be measured directly, e.g., with a piezoelectric pulse pickup as indicated above.

A suitable electrode presently preferred for attachment to the vagus nerves is a helical cuff electrode described in detail in U.S. Pat. Nos. 4,573,481 and 5,154,172, which are hereby incorporated by reference.

While the invention has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiment has been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected. For example, those skilled in the art will appreciate from the foregoing teachings of the present invention that other embodiments can be used to implement the principle of ventricular rate control during atrial fibrillation using controlled vagal stimulation. For example, both vagus nerves may be stimulated to obtain more A-V block. Alternately, only the cardiac branches of the vagus nerves (left and/or right) may be stimulated to minimize any possible gastrointestinal effects.

The embodiments illustrated in FIGS. 1 and 2 employ a catheter electrode in the right atrium and ventricle and another electrode on the left vagus nerve. An alternate embodiment could use a catheter electrode in the right pulmonary artery to stimulate the left vagus nerve, as described by Cooper et al. (Circ. Res. 1980, 46:48-57). In this way, the principle can be applied using catheter electrodes.

Another embodiment avoids blood contact by using electrodes applied to the pericardium to detect the atrial and ventricular electrograms.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of an implanted control unit according to the present invention in its operating environment showing the heart and left and right vagus nerves.

FIG. 2 is a block diagram of one form of the implanted control unit of FIG. 1.

FIG. 3 is a block diagram of another form of the implanted control unit of FIG. 1.

FIG. 4 is a graphical illustration of the relationship between ventricular rate and left vagal stimulation frequency.

FIG. 5 is a graphical illustration of the ratio of R wave rate to arterial pulse rate versus the frequency of left vagal stimulation.

BACKGROUND OF THE INVENTION

This invention relates to devices and methods for controlling ventricular rate during atrial fibrillation, and more particularly to such devices and methods employing nerve stimulation techniques.

Atrial tachycardia, flutter and fibrillation are serious arrhythmias resulting in a low cardiac output and limited exercise tolerance. At present these arrhythmias are treated with drugs, electric shock (cardioversion), or surgical destruction of the atrioventricular (A-V) node and pacemaker implantation. Drug therapy is not always effective and there are undesirable side effects. Although cardioversion abolishes some of these atrial arrhythmias, they usually return because the cause for the arrhythmia is still present. Surgical treatment is successful but leaves the subject with a limited exercise tolerance unless a rate-responsive pacemaker is implanted. These existing approaches are accepted by the medical community and biomedical engineers as the only practical choices, despite the existence of research reported in the literature for years on the subject of electrophysiological techniques involving stimulation of various nerves.

To understand the mechanism of action of an alternative system, proposed herein, for ventricular rate control by means of control of the number of atrial excitations reaching the ventricles, it is useful to review some aspects of the effect of cholinergic drive on the heart. Acetylcholine hyperpolarizes the S-A node and atrial muscle membranes, reduces the refractory period of atrial muscle and weakens the force of atrial contraction. Cholinergic drive also delays or blocks the transmission of excitation across the A-V node.

The cholinergic nerves to the heart are the right and left vagii. The right vagus innervates the S-A node, the atrial muscle and, to a much lesser degree, the A-V node. The left vagus nerve innervates the S-A node and atrial muscle to a lesser degree than it innervates the A-V node. It is well known to physiologists that stimulation of the right vagus nerve predominately slows the S-A node rate and thereby reduces heart rate. Stimulation of the left vagus nerve produces some slowing of the S-A node, prolongation of A-V conduction and partial or total A-V block. We have observed in monophasic atrial electrograms that low-frequency left vagal stimulation causes a dramatic shortening of the duration of the atrial monophasic action potential, indicating shortening of the refractory period. Although the left vagus nerve affects atrial rate to a lesser degree, transmission of excitation across the A-V node is largely regulated by the left vagus nerve.

In atrial fibrillation, the A-V node is bombarded with excitations and responds as rapidly as its refractory period will allow, resulting in rapid, irregular ventricular excitations, i.e., R waves, resulting in varying times for ventricular filling. This results in a rapid, irregular pulse with a pulse deficit. A pulse deficit exists when a ventricular excitation (R wave) does not produce a blood pressure pulse. The mean blood pressure and cardiac output are both reduced as a result of the pulse deficit.

There have been some reports of using electrodes to stimulate the vagus nerve, where such stimulation has an effect on heart rhythm. See, e.g., Bilgutay et al., Vagal Tuning, J. Thoracic Cardiovas. Surg. 56(1):71-82, July, 1968. Bilgutay et al. studied the use of vagal stimulation for treatment of supraventricular arrhythmias, angina pectoris, and heart failure. Experiments were conducted to determine the effective amplitudes, frequencies, wave shapes and pulse length of the stimulating current to achieve an optimal slowing of the heart rate by stimulating the vagus nerve, the optimal heart rate being defined as the slowest heart rate that could be attained by vagal stimulation without causing A-V dissociation or complete heart block or lowering the ventricular and aortic pressures. The experiments involved the right vagus nerve and resulted in selection of a stimulation amplitude of 6 to 10 volts, a frequency of 10 pulses per second, and 0.2 msec. pulse duration. Voltage increases were noted to decrease heart rate, and a unit triggered by the R waves of the subject's electrocardiogram is described as operating on a servo principle, but apparently in all cases the amplitude and frequency settings are fixed whenever the unit is operating. Bilgutay et al. indicated that the right vagus nerve was stimulated because its distribution is known to be mostly to the sinus node area, but mentioned one experiment in which stimulation of the left vagus slowed the ventricular beats in a dog with complete heart block.

Recognizing the possibility of bradyarrhythmia, one recently proposed approach contemplates the inclusion of cardiac pacing with vagal stimulation. This latter approach to heart rate control, which entails a bradyarrhythmia pacemaker, is described in PCT International Publication No. WO 93/21824, published Nov. 11, 1993. The addition of pacemaker circuitry and related components naturally increases the complexity and cost of the medical device. The publication mentions that stimulation frequency may be varied in a predetermined pattern from an optimum stimulation frequency, amplitude and duration determined during patient workup, if the initial delivered therapy fails to convert the tachyarrhythmia; however, there is no indication of a suitable pattern or any method of implementing it. The device described is designed to generate nerve stimulating pulses having a frequency and amplitude that, while programmable, are fixed once programmed. In essence it is an ON/OFF device that switches state in response to, e.g., the crossing of a heart rate threshold. Such ON/OFF switching, with fixed pulse characteristics, is likely to produce a hunting response, i.e., cycling of the heart rate with episodes of tachycardia.

Thus there remains the need for a system that effectively takes advantage of the phenomenon that transmission across the A-V node is largely, but not entirely, regulated by the left vagus nerve, and, more particularly, provides effective control of electrical stimulation of the vagus nerve to control the number of excitations that reach the ventricles during atrial fibrillation.

SUMMARY OF THE INVENTION

The present invention overcomes the foregoing and other disadvantages of the prior art by providing a closed-loop, variable frequency vagal stimulation apparatus for control of ventricular rate during atrial fibrillation. The apparatus includes a stimulating means for stimulating a vagal nerve at a stimulation frequency which is varied automatically in response to sensed conditions, and a controller having an output connected to said stimulating means and including means for automatically and continuously adjusting said vagal stimulation frequency as a function of the difference between actual and desired ventricular excitation rates.

According to another aspect of the present invention, there is provided an apparatus for automatically controlling ventricular rate by vagal stimulation to minimize pulse deficit during atrial fibrillation. The apparatus includes a stimulating means for stimulating a vagal nerve at a stimulation frequency which is varied automatically in response to sensed conditions, a means for detecting a ventricular excitation rate, a means for detecting an arterial pulse rate, and a processing means for comparing said ventricular excitation rate and said arterial pulse rate and automatically adjusting said vagal stimulation frequency as a function of the difference between said ventricular excitation rate and said arterial pulse rate.

A general object of the present invention is to provide an improved method and apparatus for controlling ventricular rate in the presence of atrial fibrillation.

A further object is to provide effective control of ventricular rate via vagal stimulation.

Another object of the invention is to provide an effective method and apparatus for stimulating the vagus nerve and thereby reducing ventricular rate enough to eliminate or minimize the pulse deficit which typically occurs during atrial fibrillation.

Patentzitate
Zitiertes PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US365027717. Febr. 197021. März 1972Lkb Medical Ab.Apparatus for influencing the systemic blood pressure in a patient by carotid sinus nerve stimulation
US37962217. Juli 197112. März 1974Hagfors N,UsApparatus for delivering electrical stimulation energy to body-implanted apparatus with signal-receiving means
US38501619. Apr. 197326. Nov. 1974Liss S,UsMethod and apparatus for monitoring and counteracting excess brain electrical energy to prevent epileptic seizures and the like
US391846131. Jan. 197411. Nov. 1975Cooper; Irving S.Method for electrically stimulating the human brain
US42805028. Aug. 197928. Juli 1981Intermedics, Inc.Tachycardia arrester
US457348125. Juni 19844. März 1986Huntington Institute Of Applied ResearchImplantable electrode array
US486716426. Okt. 198719. Sept. 1989Zabara; JacobNeurocybernetic prosthesis
US489061725. Nov. 19872. Jan. 1990Medtronic, Inc.Dual chamber activity responsive pacer
US49989745. Jan. 199012. März 1991Telectronics Pacing Systems, Inc.Apparatus and method for antitachycardia pacing in dual chamber arrhythmia control system
US508677230. Juli 199011. Febr. 1992Telectronics Pacing Systems, Inc.Arrhythmia control system employing arrhythmia recognition algorithm
US51078502. Nov. 199028. Apr. 1992Cardiac Pacemakers, Inc.Method and apparatus for classifying and treating cardiac arrhythmias based on atrial and ventricular activity
US514494722. März 19918. Sept. 1992Telectronics Pacing Systems, Inc.Apparatus and method for antitachycardia pacing in a arrhythmia control systems
US515417213. Nov. 198913. Okt. 1992Cyberonics, Inc.Constant current sources with programmable voltage source
US519355030. Nov. 199016. März 1993Medtronic, Inc.Method and apparatus for discriminating among normal and pathological tachyarrhythmias
US519942822. März 19916. Apr. 1993Medtronic, Inc.Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US520332618. Dez. 199120. Apr. 1993Telectronics Pacing Systems, Inc.Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US521508921. Okt. 19911. Juni 1993Cyberonics, Inc.Electrode assembly for nerve stimulation
US522249431. Juli 199129. Juni 1993Cyberonics, Inc.Implantable tissue stimulator output stabilization system
US524398030. Juni 199214. Sept. 1993Medtronic, Inc.Method and apparatus for discrimination of ventricular and supraventricular tachycardia
US533050724. Apr. 199219. Juli 1994Medtronic, Inc.Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias
US53356573. Mai 19919. Aug. 1994Cyberonics, Inc.Therapeutic treatment of sleep disorder by nerve stimulation
US548041330. Nov. 19942. Jan. 1996Telectronics Pacing Systems, Inc.Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation
US552285226. Apr. 19944. Juni 1996Incontrol, Inc.Selective cardiac activity analysis atrial fibrillation detection system and method and atrial defibrillator utilizing same
EP0688577A124. Juni 199427. Dez. 1995Pacesetter ABDevice for treating atrial tachyarrhythmia
WO1993021824A14. Jan. 199311. Nov. 1993Medtronic, Inc.Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias
Nichtpatentzitate
Referenz
1Aydin M. Bilgutay, M.D., Ilhan M. Bilgutay, B.E.E., Frederick K. Merkel, M.D., and C. Walton Lillehei, Ph.D., M.D., "Vagal Tuning", Journal of Thoracic and Cardiovascular Surgery. vol. 56, No. 1, Jul. 1968.
2Aydin M. Bilgutay, M.D., Ilhan M. Bilgutay, B.E.E., Frederick K. Merkel, M.D., and C. Walton Lillehei, Ph.D., M.D., Vagal Tuning , Journal of Thoracic and Cardiovascular Surgery . vol. 56, No. 1, Jul. 1968.
3Jaeho Kim, Joe Bocek, Harley White, Bill Crone, Cliff Alferness, John Adams, "An Atrial Fibrillation Detection Algorithm for an Implantable Atrial Defibrillator," Computers in Cardiology 1995, Sep. 10-13, 1995, Vienna, Austria, The Institute of Electrical and Electronics Engineers, Inc.
4Jaeho Kim, Joe Bocek, Harley White, Bill Crone, Cliff Alferness, John Adams, An Atrial Fibrillation Detection Algorithm for an Implantable Atrial Defibrillator, Computers in Cardiology 1995 , Sep. 10 13, 1995, Vienna, Austria, The Institute of Electrical and Electronics Engineers, Inc.
5P.E. Konrad, Ph.D., W.A. Tacker, Jr., M.D., Ph.D., J.D. Bourland, Ph.D., L.A. Geddes, Ph.D., and D. Hood, R.V.T., R.N., "A New Implantable Arterial Pulse Sensor for Detectio of Ventricular Fibrillation", Medical Instrumentation, vol. 22, No. 6, Dec., 1988.
6P.E. Konrad, Ph.D., W.A. Tacker, Jr., M.D., Ph.D., J.D. Bourland, Ph.D., L.A. Geddes, Ph.D., and D. Hood, R.V.T., R.N., A New Implantable Arterial Pulse Sensor for Detectio of Ventricular Fibrillation , Medical Instrumentation , vol. 22, No. 6, Dec., 1988.
7Terry B. Cooper, Gilbert R. Hageman, Thomas N. James, and Albert L. Waldo, "Neural Effects on Sinus Rate and Atrioventricular Conduction Produced by Electrical Stimulation from a Transvenous Electrode Catheter in the Canine Right Pulmonary Artery" Circulation Research, vol. 46, No. 1, Jan. 1980.
8Terry B. Cooper, Gilbert R. Hageman, Thomas N. James, and Albert L. Waldo, Neural Effects on Sinus Rate and Atrioventricular Conduction Produced by Electrical Stimulation from a Transvenous Electrode Catheter in the Canine Right Pulmonary Artery Circulation Research , vol. 46, No. 1, Jan. 1980.
9Tim K. Peters, H.E. Koralewski and E. Zerbst, "The Principle of Electrical Carotid Sinus Nerve Stimulation: A Nerve Pacemaker System for Angina Pectoris and Hypertension Therapy", Annals of Biomedical Engineering, vol. 8, pp. 445-458, 1980.
10Tim K. Peters, H.E. Koralewski and E. Zerbst, The Principle of Electrical Carotid Sinus Nerve Stimulation: A Nerve Pacemaker System for Angina Pectoris and Hypertension Therapy , Annals of Biomedical Engineering, vol. 8, pp. 445 458, 1980.
Referenziert von
Zitiert von PatentEingetragen Veröffentlichungsdatum Antragsteller Titel
US591387622. Sept. 199722. Juni 1999Cardiothoracic Systems, Inc.Method and apparatus for using vagus nerve stimulation in surgery
US62665643. Nov. 199924. Juli 2001Medtronic, Inc.Method and device for electronically controlling the beating of a heart
US630810422. Juni 199923. Okt. 2001Cardiothoracic Systems, Inc.Method and apparatus for using vagus nerve stimulation in surgery
US638149917. Mai 200030. Apr. 2002Cardiothoracic Systems, Inc.Method and apparatus for using vagus nerve stimulation in surgery
US643442422. Dez. 199913. Aug. 2002Medtronic, Inc.Regularization of ventricular rate during atrial tachyarrhythmia
US644950726. Sept. 200010. Sept. 2002Medtronic, Inc.Method and system for nerve stimulation prior to and during a medical procedure
US647364413. Okt. 199929. Okt. 2002Cyberonics, Inc.Method to enhance cardiac capillary growth in heart failure patients
US648744626. Sept. 200026. Nov. 2002Medtronic, Inc.Method and system for spinal cord stimulation prior to and during a medical procedure
US65115006. Juni 200028. Jan. 2003Rahme Marc MounirUse of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects
US652292627. Sept. 200018. Febr. 2003Cvrx, Inc.Devices and methods for cardiovascular reflex control
US653238826. Sept. 200011. März 2003Medtronic, Inc.Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US65427742. Juli 20011. Apr. 2003Medtronic, Inc.Method and device for electronically controlling the beating of a heart
US662898726. Sept. 200030. Sept. 2003Medtronic, Inc.Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
US666819119. Apr. 200123. Dez. 2003Neuro And Cardiac Technologies, LlcApparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator
US66909739. Aug. 200210. Febr. 2004Medtronic, Inc.Method and system for spinal cord stimulation prior to and during a medical procedure
US673547126. Sept. 200111. Mai 2004Medtronic, Inc.Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US685080126. Sept. 20011. Febr. 2005Cvrx, Inc.Mapping methods for cardiovascular reflex control devices
US689209824. Sept. 200210. Mai 2005Biocontrol Medical Ltd.Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US690729524. Juli 200214. Juni 2005Biocontrol Medical Ltd.Electrode assembly for nerve control
US691241912. März 200328. Juni 2005Medtronic, Inc.Method and device for electronically controlling the beating of a heart
US698577426. Sept. 200110. Jan. 2006Cvrx, Inc.Stimulus regimens for cardiovascular reflex control
US706907012. Mai 200327. Juni 2006Cardiac Pacemakers, Inc.Statistical method for assessing autonomic balance
US707272014. Juni 20024. Juli 2006Emory UniversityDevices and methods for vagus nerve stimulation
US714291017. Dez. 200428. Nov. 2006Emory UniversityMethods of indirectly stimulating the vagus nerve with an electrical field
US715883226. Sept. 20012. Jan. 2007Cvrx, Inc.Electrode designs and methods of use for cardiovascular reflex control devices
US71943138. Juni 200420. März 2007Cardiac Pacemakers, Inc.Baroreflex therapy for disordered breathing
US72250191. Dez. 200329. Mai 2007Medtronic, Inc.Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US726043120. Mai 200421. Aug. 2007Cardiac Pacemakers, Inc.Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device
US732179313. Juni 200322. Jan. 2008Biocontrol Medical Ltd.Vagal stimulation for atrial fibrillation therapy
US73248535. Nov. 200429. Jan. 2008Biocontrol Medical Ltd.Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US734029926. Sept. 20034. März 2008Puskas John DMethods of indirectly stimulating the vagus nerve to achieve controlled asystole
US734639823. Sept. 200418. März 2008Bio Control Medical (B.C.M.) Ltd.Electrode assembly for nerve control
US736657110. Dez. 200429. Apr. 2008Cyberonics, Inc.Neurostimulator with activation based on changes in body temperature
US739208423. Sept. 200324. Juni 2008Cardiac Pacemakers, Inc.Demand-based cardiac function therapy
US740381911. Juni 200322. Juli 2008Pacesetter, Inc.Parasympathetic nerve stimulation for control of AV conduction
US745424528. Jan. 200518. Nov. 2008Cyberonics, Inc.Trained and adaptive response in a neurostimulator
US746090624. Dez. 20032. Dez. 2008Cardiac Pacemakers, Inc.Baroreflex stimulation to treat acute myocardial infarction
US748699124. Dez. 20033. Febr. 2009Cardiac Pacemakers, Inc.Baroreflex modulation to gradually decrease blood pressure
US749316110. Mai 200517. Febr. 2009Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapy
US749974410. Mai 20063. März 2009Cardiac Pacemakers, Inc.Statistical method for assessing autonomic balance
US750916624. Dez. 200324. März 2009Cardiac Pacemakers, Inc.Automatic baroreflex modulation responsive to adverse event
US75428005. Apr. 20052. Juni 2009Cardiac Pacemakers, Inc.Method and apparatus for synchronizing neural stimulation to cardiac cycles
US756191828. Jan. 200514. Juli 2009Cyberonics, Inc.Autocapture in a neurostimulator
US756192222. Dez. 200414. Juli 2009Biocontrol Medical Ltd.Construction of electrode assembly for nerve control
US757222628. Okt. 200311. Aug. 2009Cardiac Pacemakers, Inc.System and method for monitoring autonomic balance and physical activity
US761699727. März 200310. Nov. 2009Kieval Robert SDevices and methods for cardiovascular reflex control via coupled electrodes
US762738415. Nov. 20051. Dez. 2009Bio Control Medical (B.C.M.) Ltd.Techniques for nerve stimulation
US763431718. Febr. 200515. Dez. 2009Bio Control Medical (B.C.M.) Ltd.Techniques for applying, calibrating, and controlling nerve fiber stimulation
US764387524. Dez. 20035. Jan. 2010Cardiac Pacemakers, Inc.Baroreflex stimulation system to reduce hypertension
US764388120. Jan. 20065. Jan. 2010Cyberonics, Inc.Neurostimulation with activation based on changes in body temperature
US764711413. Sept. 200412. Jan. 2010Cardiac Pacemakers, Inc.Baroreflex modulation based on monitored cardiovascular parameter
US765731026. Jan. 20062. Febr. 2010Cyberonics, Inc.Treatment of reproductive endocrine disorders by vagus nerve stimulation
US76573123. Nov. 20032. Febr. 2010Cardiac Pacemakers, Inc.Multi-site ventricular pacing therapy with parasympathetic stimulation
US766062823. März 20059. Febr. 2010Cardiac Pacemakers, Inc.System to provide myocardial and neural stimulation
US76762752. Mai 20059. März 2010Pacesetter, Inc.Endovascular lead for chronic nerve stimulation
US770687428. Juli 200527. Apr. 2010Cyberonics, Inc.Stimulating cranial nerve to treat disorders associated with the thyroid gland
US770687525. Jan. 200727. Apr. 2010Cyberonics, Inc.Modulation of drug effects by vagus nerve stimulation
US770688424. Dez. 200327. Apr. 2010Cardiac Pacemakers, Inc.Baroreflex stimulation synchronized to circadian rhythm
US771591522. Dez. 200611. Mai 2010Pacesetter, Inc.Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for prevention of atrial tachyarrhythmias
US773434810. Mai 20058. Juni 2010Cardiac Pacemakers, Inc.System with left/right pulmonary artery electrodes
US773435523. Jan. 20028. Juni 2010Bio Control Medical (B.C.M.) Ltd.Treatment of disorders by unidirectional nerve stimulation
US77473238. Juni 200429. Juni 2010Cardiac Pacemakers, Inc.Adaptive baroreflex stimulation therapy for disordered breathing
US776500010. Mai 200527. Juli 2010Cardiac Pacemakers, Inc.Neural stimulation system with pulmonary artery lead
US777870324. Juli 200217. Aug. 2010Bio Control Medical (B.C.M.) Ltd.Selective nerve fiber stimulation for treating heart conditions
US777871120. Nov. 200317. Aug. 2010Bio Control Medical (B.C.M.) Ltd.Reduction of heart rate variability by parasympathetic stimulation
US77833539. Nov. 200624. Aug. 2010Cardiac Pacemakers, Inc.Automatic neural stimulation modulation based on activity and circadian rhythm
US780519313. Juli 200728. Sept. 2010Cardiac Pacemakers, Inc.Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device
US781380511. Jan. 200612. Okt. 2010Pacesetter, Inc.Subcardiac threshold vagal nerve stimulation
US782689922. Dez. 20062. Nov. 2010Pacesetter, Inc.Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for termination of atrial tachyarrhythmias
US783316410. Aug. 200916. Nov. 2010Cardiac Pacemakers, Inc.System and method for monitoring autonomic balance and physical activity
US784027823. Juni 200023. Nov. 2010Puskas John DDevices and methods for vagus nerve stimulation
US784028027. Juli 200523. Nov. 2010Cyberonics, Inc.Cranial nerve stimulation to treat a vocal cord disorder
US78443462. Febr. 200630. Nov. 2010Biocontrol Medical Ltd.Electrode assembly for nerve control
US78605666. Okt. 200528. Dez. 2010The Cleveland Clinic FoundationSystem and method for achieving regular slow ventricular rhythm in response to atrial fibrillation
US786986727. Okt. 200611. Jan. 2011Cyberonics, Inc.Implantable neurostimulator with refractory stimulation
US786986911. Jan. 200611. Jan. 2011Pacesetter, Inc.Subcardiac threshold vagal nerve stimulation
US786988124. Dez. 200311. Jan. 2011Cardiac Pacemakers, Inc.Baroreflex stimulator with integrated pressure sensor
US786988426. Apr. 200711. Jan. 2011Cyberonics, Inc.Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US786988528. Apr. 200611. Jan. 2011Cyberonics, IncThreshold optimization for tissue stimulation therapy
US788570922. Sept. 20058. Febr. 2011Bio Control Medical (B.C.M.) Ltd.Nerve stimulation for treating disorders
US788571110. Juni 20048. Febr. 2011Bio Control Medical (B.C.M.) Ltd.Vagal stimulation for anti-embolic therapy
US790417526. Apr. 20078. März 2011Cyberonics, Inc.Trans-esophageal vagus nerve stimulation
US79041767. Sept. 20068. März 2011Bio Control Medical (B.C.M.) Ltd.Techniques for reducing pain associated with nerve stimulation
US792535227. März 200912. Apr. 2011Synecor LlcSystem and method for transvascularly stimulating contents of the carotid sheath
US796221427. Juli 200714. Juni 2011Cyberonics, Inc.Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US796222028. Apr. 200614. Juni 2011Cyberonics, Inc.Compensation reduction in tissue stimulation therapy
US797469322. Febr. 20055. Juli 2011Bio Control Medical (B.C.M.) Ltd.Techniques for applying, configuring, and coordinating nerve fiber stimulation
US797469726. Jan. 20065. Juli 2011Cyberonics, Inc.Medical imaging feedback for an implantable medical device
US797470127. Apr. 20075. Juli 2011Cyberonics, Inc.Dosing limitation for an implantable medical device
US797470726. Jan. 20075. Juli 2011Cyberonics, Inc.Electrode assembly with fibers for a medical device
US799607924. Jan. 20069. Aug. 2011Cyberonics, Inc.Input response override for an implantable medical device
US800079323. Mai 200816. Aug. 2011Cardiac Pacemakers, Inc.Automatic baroreflex modulation based on cardiac activity
US800553930. Jan. 200923. Aug. 2011Medtronic, Inc.Implantable medical device crosstalk evaluation and mitigation
US802405024. Dez. 200320. Sept. 2011Cardiac Pacemakers, Inc.Lead for stimulating the baroreceptors in the pulmonary artery
US806019716. März 200715. Nov. 2011Bio Control Medical (B.C.M.) Ltd.Parasympathetic stimulation for termination of non-sinus atrial tachycardia
US806500327. Mai 200822. Nov. 2011Cardiac Pacemakers, Inc.Demand-based cardiac function therapy
US810987910. Jan. 20067. Febr. 2012Cardiac Pacemakers, Inc.Assessing autonomic activity using baroreflex analysis
US81168832. Febr. 200714. Febr. 2012Synecor LlcIntravascular device for neuromodulation
US812169323. Okt. 200821. Febr. 2012Cardiac Pacemakers, Inc.Baroreflex stimulation to treat acute myocardial infarction
US812655221. Okt. 200828. Febr. 2012Pacesetter, Inc.Measurement of cardiac information for CRT optimziation in the presence of conduction dysfunction or atrial arrhythmia
US812655930. Nov. 200428. Febr. 2012Cardiac Pacemakers, Inc.Neural stimulation with avoidance of inappropriate stimulation
US812656024. Dez. 200328. Febr. 2012Cardiac Pacemakers, Inc.Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US813135923. Apr. 20086. März 2012Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapy
US813137330. März 20106. März 2012Cardiac Pacemakers, Inc.Baroreflex stimulation synchronized to circadian rhythm
US815050829. März 20073. Apr. 2012Catholic Healthcare WestVagus nerve stimulation method
US817066814. Juli 20061. Mai 2012Cardiac Pacemakers, Inc.Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US817570512. Okt. 20048. Mai 2012Cardiac Pacemakers, Inc.System and method for sustained baroreflex stimulation
US818046218. Apr. 200615. Mai 2012Cyberonics, Inc.Heat dissipation for a lead assembly
US819528930. Nov. 20095. Juni 2012Cardiac Pacemakers, Inc.Baroreflex stimulation system to reduce hypertension
US820459124. Jan. 200719. Juni 2012Bio Control Medical (B.C.M.) Ltd.Techniques for prevention of atrial fibrillation
US820460325. Apr. 200819. Juni 2012Cyberonics, Inc.Blocking exogenous action potentials by an implantable medical device
US821918829. März 200710. Juli 2012Catholic Healthcare WestSynchronization of vagus nerve stimulation with the cardiac cycle of a patient
US82244373. Okt. 200817. Juli 2012Cvrx, Inc.Baroreflex activation for sedation and sleep
US823902824. Apr. 20097. Aug. 2012Cyberonics, Inc.Use of cardiac parameters in methods and systems for treating a chronic medical condition
US82497056. März 200821. Aug. 2012Cvrx, Inc.Devices, systems, and methods for improving left ventricular structure and function using baroreflex activation therapy
US824970830. Jan. 200921. Aug. 2012Medtronic, Inc.Implantable medical device crosstalk evaluation and mitigation
US826041230. Jan. 20094. Sept. 2012Medtronic, Inc.Implantable medical device crosstalk evaluation and mitigation
US826042625. Jan. 20084. Sept. 2012Cyberonics, Inc.Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US828050510. März 20092. Okt. 2012Catholic Healthcare WestVagus nerve stimulation method
US828538921. Juli 20109. Okt. 2012Cardiac Pacemakers, Inc.Automatic neural stimulation modulation based on motion and physiological activity
US829594623. Mai 201123. Okt. 2012Cyberonics, Inc.Electrode assembly with fibers for a medical device
US830662723. Mai 20116. Nov. 2012Cyberonics, Inc.Dosing limitation for an implantable medical device
US831571330. Apr. 200920. Nov. 2012Medtronic, Inc.Techniques for placing medical leads for electrical stimulation of nerve tissue
US832102327. Jan. 200927. Nov. 2012Cardiac Pacemakers, Inc.Baroreflex modulation to gradually decrease blood pressure
US832643819. Okt. 20094. Dez. 2012Bio Control Medical (B.C.M.) Ltd.Techniques for nerve stimulation
US833204716. Nov. 200511. Dez. 2012Cardiac Pacemakers, Inc.System and method for closed-loop neural stimulation
US83374041. Okt. 201025. Dez. 2012Flint Hills Scientific, LlcDetecting, quantifying, and/or classifying seizures using multimodal data
US83699547. März 20115. Febr. 2013Synecor LlcSystem and method for transvascularly stimulating contents of the carotid sheath
US838266729. Apr. 201126. Febr. 2013Flint Hills Scientific, LlcDetecting, quantifying, and/or classifying seizures using multimodal data
US838605624. Febr. 200526. Febr. 2013Bio Control Medical (B.C.M.) Ltd.Parasympathetic stimulation for treating atrial arrhythmia and heart failure
US839197026. Aug. 20085. März 2013The Feinstein Institute For Medical ResearchDevices and methods for inhibiting granulocyte activation by neural stimulation
US839197717. Jan. 20125. März 2013Pacesetter, Inc.Measurement of cardiac information for CRT optimziation in the presence of conduction dysfunction or atrial arrhythmia
US839656018. Nov. 200412. März 2013Cardiac Pacemakers, Inc.System and method for closed-loop neural stimulation
US201003319081. Sept. 201030. Dez. 2010Farazi Taraneh GhaffariSubcardiac threshold vagal nerve stimulation
USRE3865415. Nov. 200123. Nov. 2004Medtronic, Inc.Method and device for electronically controlling the beating of a heart
USRE4296128. Jan. 200522. Nov. 2011St. Jude Medical, Atrial Fibrillation Division, Inc.Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects
EP1118352A218. Jan. 200125. Juli 2001Pacesetter, Inc.Implantable cardiac stimulation device and method for prolonging atrial refractoriness
EP1897586A17. Sept. 200712. März 2008Biocontrol Medical Ltd.Techniques for reducing pain associated with nerve stimulation
WO2001026729A112. Okt. 200019. Apr. 2001Cyberonics, Inc.Method to enhance cardiac capillary growth in heart failure patients
WO2003099377A123. Mai 20034. Dez. 2003Ayal, ShaiSelective nerve fiber stimulation for treating heart conditions